Summary
Alnylam Pharmaceuticals, Inc. reported strong financial performance for the six months ended June 30, 2026, driven by significant growth in net product revenues, primarily from AMVUTTRA. The company achieved a substantial increase in net product revenues, up 94% year-over-year, reaching $2.21 billion, with AMVUTTRA sales more than doubling to $1.90 billion. This growth is largely attributed to the expansion of AMVUTTRA for ATTR-CM in the US and other global markets. While net revenues from collaborations decreased by 20%, this was primarily due to the completion of certain collaboration activities and the wind-down of research terms, partially offset by increased revenue from the Roche collaboration. The company reported a net income of $370.5 million for the six-month period, a significant improvement from a net loss of $90.5 million in the prior year, indicating a strong shift towards profitability. The balance sheet shows healthy liquidity with $1.71 billion in cash and cash equivalents and $1.60 billion in marketable debt securities.
Key Highlights
- 1Net product revenues surged by 94% to $2.21 billion for the first six months of 2026, compared to $1.14 billion in the same period of 2025.
- 2AMVUTTRA sales demonstrated exceptional growth, increasing by 137% to $1.90 billion in the first six months of 2026, largely driven by its expanded use in ATTR-CM.
- 3ONPATTRO sales decreased by 62% to $38.9 million in the first six months of 2026, indicating a strategic shift or market dynamics favoring AMVUTTRA within the TTR franchise.
- 4The company achieved net income of $370.5 million for the first six months of 2026, a significant turnaround from a net loss of $90.5 million in the comparable period of 2025.
- 5Total cash, cash equivalents, and restricted cash increased to $1.71 billion as of June 30, 2026, providing a strong liquidity position.
- 6Marketable debt securities also saw substantial growth, reaching $1.60 billion as of June 30, 2026, up from $1.25 billion at the end of 2025.
- 7Research and development expenses increased by 32% to $778 million, reflecting continued investment in pipeline advancement, notably Phase 3 trials for nucresiran and zilebesiran.